Calcium homeostasis is dysregulated in Parkinsonian patients with L-DOPA-induced dyskinesias

Clinical Neuropharmacology

Volumn 32, Issue 3, 2009, Pages 133-139

  Blandini, Fabio ^a   Bazzini, Eleonora ^a   Marino, Franca ^b   Saporiti, Federica ^b   Armentero, Marie Therese ^a   Pacchetti, Claudio ^a   Zangaglia, Roberta ^a   Martignoni, Emilia ^c,d   Lecchini, Sergio ^b   Nappi, Giuseppe ^a,e   Cosentino, Marco ^b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine receptors; Lymphocytes; Parkinson disease; Second messengers; Therapy

Indexed keywords

CABERGOLINE; CALCIUM; CYCLIC AMP; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; LEVODOPA; MESSENGER RNA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; BLOOD SAMPLING; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSKINESIA; HUMAN; MONOTHERAPY; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AKATHISIA, DRUG-INDUCED; ANTIPARKINSON AGENTS; CALCIUM; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CASE-CONTROL STUDIES; CYCLIC AMP; FEMALE; HOMEOSTASIS; HUMANS; IONOPHORES; LACTONES; LEVODOPA; LYMPHOCYTES; MALE; MIDDLE AGED; MITOGENS; PARKINSON DISEASE; PHYTOHEMAGGLUTININS; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D5; RNA, MESSENGER; SESQUITERPENES;

EID: 67651163577     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0B013E3181761466     Document Type: Article

References (45)

1. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-S7. (Pubitemid 30949970)
2. Linazasoro G. New ideas on the origin of L-dopa-induced dykinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391-397. (Pubitemid 41039214)
3. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-dopa-induced dyskinesia. Nat Neurosci 2003;6:501-506. (Pubitemid 36514698)
4. Fienberg AA, Hiroi N, Mermelstein PG, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998;281:838-842. (Pubitemid 28376047)
5. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26. (Pubitemid 40053311)
6. Hakansson K, Lindskog M, Pozzi L, et al. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Relat Disord 2004;10:281-286. (Pubitemid 38757808)
7. Konradi C, Westin JE, Carta M, et al. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 2004;17:219-236. (Pubitemid 39345778)
8. Prigione A, Begni B, Galbussera A, et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 2006;23:36-43. (Pubitemid 43903629)
9. Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 2002;58:1809-1815. (Pubitemid 34663582)
10. Blandini F, Sinforiani E, Pacchetti C, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006;66:529-534. (Pubitemid 43739882)
11. Blandini F, Cosentino M, Mangiagalli A, et al. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J Neural Transm 2004;111:1017-1030. (Pubitemid 39037123)
12. Santambrogio L, Lipartiti M, Bruni A, et al. Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol 1993;45: 113-119.
13. Ricci A, Bronzetti E, Mignini F, et al. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 1999;96:234-240. (Pubitemid 29234498)
14. Cosentino M, Rasini E, Colombo C, et al. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic Biol Med 2004;36:1233-1240. (Pubitemid 38526317)
15. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450. (Pubitemid 15114340)
16. Cosentino M, Marino F, Bombelli R, et al. Stimulation with phytohaemagglutinin induces the synthesis of catecholamines in human peripheral blood mononuclear cells: role of protein kinase C and contribution of intracellular calcium. J Neuroimmunol 2002;125:125-133. (Pubitemid 34327461)
17. Geiszt M, Kaldi K, Szeberenyi JB, et al. Thapsigargin inhibits Ca2+ entry into human neutrophil granulocytes. Biochem J 1995;305:525-528.
18. Fossati G, Moulding DA, Spiller DG, et al. The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J Immunol 2003;170:1964-1972. (Pubitemid 36197416)
19. Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47: S70-S78.
20. Picconi B, Pisani A, Barone I, et al. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 2005;26:779-783. (Pubitemid 41427517)
21. Martignoni E, Blandini F, Godi L, et al. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DoPA. Free Radic Biol Med 1999;27:428-437.
22. McKenna F, McLaughlin PJ, Lewis BJ, et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002;132:34-40. (Pubitemid 35333323)
23. Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol 2005;169:161-171. (Pubitemid 41528789)
24. Torres KC, Antonelli LR, Souza AL, et al. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 2005;166:144-157.
25. Levite M, Chowers Y, Ganor Y, et al. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol 2001;31:3504-3512. (Pubitemid 34030963)
26. + T cells via dopamine receptor D3. J Immunol 2006;176:848-856. (Pubitemid 43099681)
27. + T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 2001;9:23-33. (Pubitemid 32642070)
28. + regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007;109:632-642. (Pubitemid 46105964)
29. Ferrari M, Cosentino M, Marino F, et al. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem Pharmacol 2004;67:865-873. (Pubitemid 38201632)
30. Nagai Y, Ueno S, Saeki Y, et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996;46:791-795. (Pubitemid 26099651)
31. Volicer L, Beal MF, Direnfeld LK, et al. CSF cyclic nucleotides and somatostatin in Parkinson's disease. Neurology 1986;36:89-92. (Pubitemid 16186057)
32. Covickovic-Sternic N, Kostic VS, Djuricic BM, et al. Cyclic nucleotides in cerebrospinal fluid of drug-free Parkinson patients. Eur Neurol 1987;27:24-28. (Pubitemid 17086663)
33. Hossain MA, Weiner N. Dopaminergic functional supersensitivity: effects of chronic Ldopa and carbidopa treatment in an animal model of Parkinson's disease. J Pharmacol Exp Ther 1993;267: 1105-1111. (Pubitemid 24068672)
34. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003;16:S3-S7. (Pubitemid 38328107)
35. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701-712.
36. Lachowicz JE, Sibley DR. Molecular characteristics of mammalian dopamine receptors. Pharmacol Toxicol 1997;81: 105-113.
37. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005;20:919-931.
38. Gardoni F, Picconi B, Ghiglieri V, et al. OPA induced dyskinesia. J Neurosci 2006;26:2914-2922.
39. Yasumoto F, Negishi T, Ishii Y, et al. Dopamine receptor 2 regulates L-type voltage-gated calcium channel in primary cultured mouse midbrain neural network. Cell Mol Neurobiol 2004;24:877-882. (Pubitemid 40174237)
40. Wolf ME, Kapatos G. Stimulation of D2 dopamine receptors decreases intracellular calcium levels in rat anterior pituitary cells but not striatal synaptosomes: a flow cytometric study using indo-1. Synapse 1989;4:353-370. (Pubitemid 20044792)
41. Malgaroli A, Vallar L, Elahi FR, et al. Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem 1987;262:13920-13927.
42. Rajda C, Dibo G, Vecsei L, et al. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients. Neuroimmunomodulation 2005;12:81-84. (Pubitemid 40529253)
43. Rodgers KJ, Hume PM, Morris JG, et al. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa. J Neurochem 2006;98:1061-1067.
44. Blandini F, Nappi G, Fancellu R, et al. Modifications of plasma and platelet levels of LDOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. J Neural Transm 2003;110:911-922. (Pubitemid 36981407)
45. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and L-dopa metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102-1104. (Pubitemid 32493598)